What happened with SMMT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Summit Therapeutics is a drug developer whose business centers on ivonescimab, a cancer antibody licensed from Akeso. The drug is designed to block both a pathway that restrains immune responses and a signal involved in blood-vessel growth. It remains in clinical development, and Summit has no product-sales revenue. The company has funded its operations primarily by issuing shares rather than selling medicines.
Summit holds development and commercialization rights in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa; Akeso retains rights elsewhere. If approved, sales would depend on physicians prescribing the drug and government and private payors covering treatment. Summit controls commercial strategy and pricing in its territory but must pay Akeso approval and sales milestones and royalties on sales.
The business depends heavily on this one drug and on Akeso, currently its sole supplier of the drug substance while additional sources are being established. The FDA is reviewing an application for ivonescimab with chemotherapy in a specific lung-cancer setting and has said a statistically significant overall-survival benefit is necessary for authorization. Approval is not assured, and separate approvals are required in other jurisdictions. Summit also needs additional capital to fund development and its licensing obligations.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Summit Therapeutics’ prospects hinge on ivonescimab’s clinical results and approvals, with Akeso supplying the licensed technology and currently acting as its sole drug-substance manufacturer.
Merck’s established lung-cancer treatment Keytruda competes with Summit Therapeutics’ ivonescimab, while its licensed bispecific antibody LM-299 adds another development rival. Merck sells medicines to wholesalers, hospitals and other healthcare buyers; watch LM-299’s clinical results for the efficacy and safety ivonescimab may need to beat.
BioNTech’s pumitamig could narrow Summit Therapeutics’ opportunity for ivonescimab in overlapping cancer settings: this PD-L1/VEGF bispecific antibody is already in global Phase III trials. BioNTech commercializes the COVID-19 vaccine Comirnaty, but its pumitamig results in first-line non-small-cell lung cancer are the news most relevant to Summit.
Bristol Myers Squibb challenges Summit Therapeutics through both the cancer medicine it sells, Opdivo, and pumitamig, the Phase III bispecific antibody it co-develops with BioNTech. Watch pumitamig’s lung-cancer trial results: they could change how strong ivonescimab’s efficacy and safety need to be to win adoption.
Pfizer’s PF’4404 competes for cancer settings targeted by Summit Therapeutics’ ivonescimab; Pfizer holds rights to develop it worldwide outside China. Pfizer earns most of its revenue from selling medicines, but for Summit holders the key news is this PD-1/VEGF bispecific antibody’s efficacy, safety and approval progress in first-line non-small-cell lung cancer.
Crescent Biopharma, Inc. is developing a much earlier rival to Summit Therapeutics: its CR-001 PD-1/VEGF bispecific antibody is designed to reproduce important properties of ivonescimab. CR-001 began a global Phase 1/2 trial in the first quarter of 2026; patient results, rather than its design alone, will show whether it can deliver comparable effects, which Crescent says are not assured.
AstraZeneca’s marketed lung-cancer medicine Imfinzi and additional immunotherapies in development compete with Summit Therapeutics’ ivonescimab in non-small-cell lung cancer. Watch its lung-cancer immunotherapy results for evidence of safer or more effective alternatives that could make ivonescimab harder to adopt.
AbbVie adds a direct development rival to Summit Therapeutics’ ivonescimab through RC148, a competing PD-(L)1/VEGF bispecific antibody for which it holds rights outside Greater China. The medicine developer and seller’s RC148 clinical and approval progress is the relevant news to watch, rather than its broader drug sales.
Revolution Medicines links its cancer-drug development directly to Summit Therapeutics by testing its drugs that block active RAS proteins alongside ivonescimab, not by buying or supplying drugs. The first patient has been dosed; safety and efficacy results from these solid-tumor combination trials will show how ivonescimab performs with Revolution’s RAS inhibitors.
Compass Therapeutics, Inc. is developing CTX-10726, a PD-1/VEGF-A bispecific antibody that directly rivals Summit Therapeutics’ ivonescimab. Compass has no product-sales revenue yet, so CTX-10726’s clinical results—not current medicine sales—are what could reveal another competitive option.
Johnson & Johnson’s amivantamab treatment regimens compete with Summit Therapeutics’ ivonescimab for patients with EGFR-mutated non-small-cell lung cancer after targeted therapy.
Regeneron’s marketed immunotherapy Libtayo, also called cemiplimab, competes with Summit Therapeutics’ ivonescimab in first-line treatment of non-small-cell lung cancer.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report may show whether pumitamig, which it co-develops with BioNTech, is advancing in lung-cancer trials and raising the bar for Summit’s ivonescimab.
Look for meaningful progress in lung-cancer trials and any efficacy or safety evidence. Convincing results could give doctors and patients a stronger alternative, making Summit’s case for ivonescimab’s advantage more important; limited results would leave pumitamig a less established threat.
Compass Therapeutics, Inc. earningsCMPX
Compass Therapeutics, Inc.’s report may show whether patient results for its CTX-10726 antibody point to another potential option alongside Summit’s ivonescimab.
Look for patient data from CTX-10726 trials and whether it shows clinically meaningful activity with acceptable safety. Positive evidence would suggest ivonescimab is not the only contender using this approach and could raise the bar for Summit; poor results or no data would leave the challenge unproven.
